89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors

PURPOSE: We evaluated biodistribution and tumor targeting of (89)Zr-lumretuzumab before and during treatment with lumretuzumab, a human epidermal growth factor receptor 3 (HER3)-targeting monoclonal antibody. EXPERIMENTAL DESIGN: 20 patients with histologically confirmed HER3-expressing tumors recei...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Bensch, Frederike, Lamberts, Laetitia E., Smeenk, Michaël M., Jorritsma-Smit, Annelies, Lub-de Hooge, Marjolijn N., Terwisscha van Scheltinga, Anton G.T., de Jong, Johan R., Gietema, Jourik A., Schröder, Carolien P., Thomas, Marlene, Jacob, Wolfgang, Abiraj, Keelara, Adessi, Celine, Meneses-Lorente, Georgina, James, Ian, Weisser, Martin, Brouwers, Adrienne H., de Vries, Elisabeth G.E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5642894/
https://ncbi.nlm.nih.gov/pubmed/28733442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0311
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak